抑制ECV304细胞内EOLA1基因表达后效应观察

目的观察抑制人脐静脉内皮细胞系ECV304细胞内内皮高表达脂多糖相关因子1（endothe-lial-overexpressed lipopolysaccharide-associated factor 1,EOLA1）基因表达后细胞生长的变化。方法构建EGFP-EOLA1融合蛋白表达载体pEGFP-N2/EOLA1,转染ECV304细胞,G418压力筛选获得稳定表达株;设计靶点特异性的寡核苷酸,连接到经BamHⅠ和HindⅢ酶切线性化的pSlincer3.1/H1质粒上。转染重组质粒到稳定表达EGFP-EOLA1融合蛋白的ECV304细胞,检测靶基因的抑制情况,观察EOLA1表达被抑制后细胞生长的改变。结果抑制EOLA1表达后ECV304细胞生长明显减慢。结论EOLA1基因在细胞内参与了细胞生长的调控。     

人TALL-1基因毕赤酵母表达载体的构建与鉴定

目的克隆人TALL-1基因全长及其胞外区片段，构建人TALL-1及其胞外区蛋白毕赤酵母分泌型表达载体。方法从人新鲜淋巴结组织中提取总RNA，利用RT-PCR技术扩增人TALL-1及其胞外区基因编码区序列，构建人TALL-1及其胞外区cDNA毕赤酵母表达载体，并进行序列测定。结果克隆获得的858bp和459bp片段与文献报道的人TALL-1全长及其胞外区基因编码区cDNA序列一致，将目的基因插入酵母表达载体pPiC-9Ka因子分泌信号肽下游。结论本实验为大量获得人TALL-1蛋白及其可溶性功能蛋白，以及探讨其生物学性能和未来在临床上的应用奠定了实验基础。     

胃癌及其癌前病变相关新基因GP1的克隆

目的 比较胃癌、癌前病变和正常胃黏膜之间基因表达的差异,寻找与胃癌发生、发展相关的基因。方法 用荧光mRNA差异显示技术（FDD）分离差异表达的基因片段,进行PCR再扩增。将扩增的cDNA片段克隆后进行测序,测序结果提交GenBank,经BLAST软件检索进行同源性分析。差异条带经Northern杂交验证。应用SMART RACE（Rapid Amplication of cDNA Ends）技术扩增GP1的全长cDNA,并应用生物信息学技术预测该基因的生物学功能。结果 发现1个在胃癌及癌前病变组织中低表达的而且在GenBank数据库中未找到同源序列的cDNA片段,为新的基因片段,并获得GenBank登陆号CD454989。GP1的全长cDNA序列为1362bp,编码生物学功能未明的具有267氨基酸的蛋白质BAA91562.1。结论 发现了一个在胃癌、癌前病变及正常胃黏膜组织中差异表达的新基因,它可能参与了胃癌的发生、发展过程。     

NF-κB p50亚基同源结构域相互作用多肽的筛选

目的：应用酵母双杂交技术筛选获得与核因子κB（NF-κB）p50亚基同源结构域（RHD）相互作用的多肽。方法：应用酵母双杂交技术，以NF—κBp 50 RHD为诱饵，筛选16肽cDNA文库，寻找与其相互作用的多肽，应用β-gal试验、酵母交配试验及一对-酵母回复性杂交等方法筛除假阳性克隆，确定阳性克隆。结果：经酵母双杂交及反复的排查，共获得8个阳性克隆。通过GenBank进行检索，未发现与之相匹配的蛋白序列。结论：获得8个与NF-κB p50 RHD相互作用的新型多肽，多肽的功能需进一步验证。     

激活素受体相互作用蛋白3的基因克隆及其免疫学特性研究

目的：研究新克隆的激活素受体相互作用蛋白3（ActRIP3）的免疫学特性和其介导Ser／Thr激酶型受体胞内信号传导的作用。方法：以酵母双杂交法发现的ActRIP基因片段作为探针，从小鼠脑cDNA文库中克隆ActRIP3基因。EIA法分析其与激活素ⅡA型受体（ActRⅡA）结合能力，Westernblot杂交检测成熟蛋白在组织中的表达，免疫组化染色分析其在脑组织中的分布，采用pcDNA-AetRIP3与CAGA-1ux报告基因质粒共转染HEK293细胞分析信号传导作用。结果：克隆的ActRIP3基因全长1197bp，编码101个氨基酸残基，EIA分析显示ActRIP3与ActRⅡA具有特异性结合作用，这种作用与ActRIP3的N末端氨基酸序列有关。Westernblot杂交显示天然ActRIP3相对分子质量约为14000，在多种组织表达，免疫组化染色显示其在脑组织中的分布以海马及下丘脑为主。通过表达ActRIP3可促进激活索诱导的特异性基因转录活性。结论：ActRIP3属于ActRIP家族新成员，具有特异结合ActRⅡA的能力，并具有促进激活素信号传导的作用。     

表达人IL-17F重组腺病毒载体的构建及其表达产物的功能研究

目的构建表达人白细胞介素IL-17F （hIL-17F）的重组腺病毒载体（Ad-hIL-17F），为进行hIL-17F基因表达抑制血管形成和抑瘤效应的研究奠定基础。方法以pUCm-T/hIL-17F重组质粒为模板PCR扩增hIL-17F，酶切连接到带有GFP标记的pAdTrack-CMV转移质粒上，PmeⅠ线性化重组质粒pAdTrack-CMV-hIL-17F，与腺病毒骨架质粒pAdEasy-1共转化BJ5183细菌，经同源重组，获得同源重组腺病毒质粒pAdEasy-1-pTrack-CMV-hIL-17F经PacⅠ线性化后转染QBI-293A细胞，收获Ad-hIL-17F，用RT-PCR和间接免疫荧光法鉴定人IL-17F基因表达。 MTT法检测hIL-17F基因表达对ECV304细胞的生长抑制作用， ELISA法检测人血管内皮生长因子（ VEGF）和血管生成素（ Ang-1）基因在293A细胞、ECV304细胞中的表达水平；实时定量RT-PCR检测Ad-hIL-17F对293A细胞中人VEGF转录的影响。结果测序显示hIL-17F序列正确，RT-PCR和间接免疫荧光法检测到了IL-17 F基因的表达。 Ad-hIL-17 F能显著抑制ECV304细胞的生长，抑制人VEGF和Ang-1基因在293 A细胞、ECV304细胞中的表达。结论成功构建和获得了hIL-17F的重组腺病毒载体（Ad-hIL-17F）， Ad-hIL-17 F可通过下调VEGF和Ang-1的分泌而抑制血管形成。     

NALP3富含亮氨酸重复序列结构域识别人细胞周期蛋白H和禽冠状病毒蛋白

 目的：寻找与NALP3富含亮氨酸重复序列（leucine-rich repeat, LRR）结构域相互作用的蛋白质分子。方法：克隆NALP3富含亮氨酸重复序列（NALP3-LRR）结构域的DNA序列并经测序检验。应用酵母双杂交技术,构建以NALP3-LRR结构域为诱饵基因的酵母双杂交载体,对人胚肺cDNA文库进行杂交筛选,经酵母回交实验验证蛋白质在酵母细胞内的相互作用并对阳性克隆的DNA进行序列测定和生物信息学分析。将筛选到的阳性克隆进一步用免疫共沉淀实验验证NALP3-LRR结构域与阳性蛋白之间相互作用的可靠性。结果：成功克隆NALP3-LRR结构域的DNA序列并经测序检验正确。用酵母双杂交技术对人胚肺cDNA文库进行酵母杂交筛选共获得4个阳性克隆。免疫共沉淀实验证实能与NALP3-LRR结构域发生相互作用的阳性蛋白是人细胞周期蛋白H和禽传染性支气管炎病毒株Cal99的ORF1a。结论：NALP3的富含亮氨酸重复序列结构域能与人细胞周期蛋白H和禽冠状病毒蛋白发生相互作用。     

酵母双杂交技术筛选NECL1胞内区的结合蛋白

目的 筛选人源膜表面黏附分子NECL1蛋白胞内区相互作用蛋白。 方法 构建含人NECL1蛋白胞内区氨基酸编码序列的诱饵质粒pGBKT7-NECL1C,对人胎脑cDNA文库进行酵母双杂交筛选。用GST pull down实验进行体外蛋白相互作用的验证。结果 酵母双杂交阳性克隆测序后显示共存在9段不同序列（存在重复克隆）。比对氨基酸序列得到5个可能相互作用蛋白。通过GST pull down 实验验证了其中两个蛋白与NECL1胞内区的相互作用。结论 应用酵母双杂交系统,获得了一些候选的NECL1胞内区相互作用蛋白。     

酵母双杂合系统AD端阴离子交换蛋白C-末端表达质粒的构建

利用PCR方法，从阴离子交换蛋白1（AE1）全长cDNA中扩增出约350bp c末端cDNA片段，测序后将其克隆至pGADT7载体上，用醋酸锂法构建好的pADT7-AE1-c末端转染酵母菌HA109，观察其在选择性培养基上的表达情况。结果表明，获得了530bp AE1c－末端cDNA,pGADT7-AE1-c末端对酵母无毒性，不能激活检测基因，可作为酵母双杂合系统中的靶基因。     

低密度脂蛋白诱导下调的新基因cDNA的克隆及组织表达

用改进的mRNA差异显示．PCR技术分析ECV304在低密度脂蛋白的诱导下表达水平明显差异的cDNA。获得-差异表达的265bp新EST；以该EST为探针，从人主动脉cDNA文库中筛选到一个1726bp的cDNA克隆，其748-1266bp之间的519个碱基构成一个完整的开放阅读框架，编码172个氨基酸组成的蛋白质。其羧基端94-172区间氨基酸序列中含有三个重复的C2H2型锌指蛋白基序CX2CX3FX5LX2HX3H，Northen Blot证实两组ECV304中均出现一条1．7kb的区带，LDL诱导后其表达降低了2．2倍。与差异显示-PCR的结果一致，该基因被定名为LRZFG。LRZFG是多组织表达的基因，其在动脉粥样硬化早期病理反应的作用有待于进一步研究。     

Cloning and characterization of a novel gene which encodes a protein interacting with the mitosis-associated kinase-like protein NTKL

NTKL is an evolutionarily conserved kinase-like protein. The cell-cycle-dependent centrosomal localization of NTKL suggested that it was involved in centrosome-related cellular function. The mouse NTKL protein is highly homologous with human NTKL. A novel mouse protein was identified as an NTKL-binding protein (NTKL-BP1) by yeast two-hybrid screening, and the full-length cDNA was amplified based on the result of a sequence data analysis cloning strategy. The full-length cDNA sequence of the NTKL-BP1 gene consists of 2,537 bp, which encode 368 amino acids. A database search revealed that homologues of NTKL-BP1 exist in different organisms, including Arabidopsis thaliana, Drosophila melanogaster, Plasmodium falciparum, Geobacter metallireducens, Anopheles gambiae and human. It suggests that NTKL-BP1 is an evolutionarily conserved protein. The expression of NTKL-BP1 was observed in multiple normal mouse tissues. The interaction of the two proteins was confirmed by co-immunoprecipitation. Moreover, immunofluorescent staining indicated that NTKL and NTKL-BP1 were all localized in the cytoplasm.     

Cloning and sequencing of a novel human gene which encodes a putative hydroxylase

Using a conventional two-hybrid technique with MAWD as bait protein, a novel full-length cDNA was isolated and sequenced from a human liver cDNA library. This cDNA consists of 2575 base pairs and has a predicted open reading frame encoding 255 amino acids. Overall, it is similar to the catalytic enzyme PHZF, catalyzing the hydroxylation of phenazine-1-carboxylic acid to 2-hydroxy-phenazine-1-carboxylic acid. Polymerase chain reaction-based mapping with both a monochromosomal hybrid panel and radiation hybrid cell panels placed the gene to human chromosome 10q21.1 near the marker D10S210. Received: December 15, 2000 / Accepted: January 22, 2001     

血管内皮细胞(ECV304)表达的HLA-G1对NK细胞杀伤活性的抑制作用

目的:证实HLA-G1分子能够抑制NK细胞对同种血管内皮细胞系的杀伤作用。方法:采用脂质体介导的DNA转染技术,以构建的真核表达质粒pcDNA3-HLA-G1转染人脐静脉内皮细胞系ECV304,再用免疫荧光法检测表达的HLA-G1分子。并用MTT比色法检测HLA-G1对NK细胞杀伤活性的影响。结果:ECV304细胞上可稳定表达HLA-G1。NK细胞对空质粒pcDNA3转染的ECV304细胞的杀伤率为(50.6±18.1)%;而对pcDNA3-HLA-G1转染的ECV304细胞的杀伤率为(29.7±11.4)%,两者差异具有显著意义(P<0.01)。结论:HLA-G1分子可明显抑制NK细胞对同种血管内皮细胞的杀伤效应。     

ICAP1α及突变体T38A、I138A在内皮细胞ECV304整合素β1内化中的作用

目的:探讨ICAP1α及突变体T38A、I138A在内皮细胞ECV304内化整合素β1中的作用和机制。方法:构建pAAV-ICAP1α及其突变体pAAV-T38A和pAAV-I138A真核表达载体,转染ECV304。ECV304分为ICAP1α组、T38A组、I138A组、绿色荧光蛋白(GFP)组和未转染组,用NHS-SS-Biotin标记整合素β1,并利用生物素-亲和素系统以及Westernblot检测整合素β1内化情况。结果:各组细胞转染的质粒均稳定表达;Westernblot检测ICAP1α组、T38A组、I138A组、GFP组、未转染组内化的整合素β1相对光密度值分别为1.07±0.04、0.68±0.06、0.70±0.02、0.87±0.06、0.88±0.04;与GFP组和未转染组比较,ICAP1α组整合素β1内化明显增多(P<0.05);与GFP组、未转染组和ICAP1α组比较,T38A组和I138A组整合素β1内化明显减少(P<0.05),GFP组与未转染组无差别(P>0.05)。结论:转染ICAP1α后内皮细胞ECV304表面整合素β1内化增加,而转染T38A和I138A后内皮细胞ECV304表面整合素β1内化减少;ICAP1α可能通过第38位的苏氨酸残基(38Tyr)和第138位的异亮氨酸残基(138Ile)调控整合素β1的内化。     

血管形成抑制因子tumstatin45-132的基因克隆、表达和生物学活性

目的: 克隆人tumstatin全长编码区基因及编码tum statin45-132的基因, 在大肠杆菌中表达。方法: 采用RT PCR从人胚肾细胞系 293细胞中克隆人的tumstatin全长编码基因, 继以PCR扩增tumstatin45-132 (45 -132位氨基酸 )编码基因, PCR产物克隆到pBV220载体中, 测序证实后, 转化E.coliBL21, 于 42℃进行热诱导表达。用SDS -PAGE分析表达产物, 对重组蛋白纯化后用内皮细胞增殖试验测定其生物学活性。结果: RT- PCR扩增出tumstatin全长编码基因, 以PCR扩增出tumstatin45-132的编码基因, 经序列分析证实与GenBank中的序列完全一致。以含有tumstatin45-132编码基因的表达载体转化E.coliBL21后, 可表达出相对分子质量(Mr)为 9 600的重组蛋白。表达产物的蛋白量占菌体蛋白量的 10%, 纯化后能抑制内皮细胞的增殖。结论: 成功克隆全长tumstatincDNA, 并在大肠杆菌中表达重组tumstatin45-132蛋白, 证实其具有抑制内皮细胞增殖的活性。     

酵母双杂交筛选与单剪接型2.2 kb乙型肝炎病毒剪接特异性新蛋白相互作用的肝细胞蛋白

目的 筛选与单剪接型2.2 kb乙型肝炎病毒(HBV)剪接特异性新蛋白相互作用的肝细胞蛋白.方法 PCR扩增单剪接型2.2 kb HBV剪接特异性新基因TPss并克隆于诱饵载体pGBKT7,在证实TPss蛋白不具有自激活作用的前提下,以酵母双杂交系统筛查与TPss蛋白相互作用的肝细胞蛋白,进而通过哺乳动物细胞双杂交实验验证候选肝细胞蛋白与TPss蛋白在Huh7和HepG2肝细胞中的相互作用.结果 构建酵母双杂交诱饵载体pGBKT7-TPss,Western blot显示其在酵母中表达TPss蛋白.酵母双杂交筛选及哺乳动物细胞双杂交证实TPss蛋白可与4种肝细胞蛋白相互作用,即组织蛋白酶B、微粒体环氧化物水解酶、组织蛋白酶D与纤维蛋白原γ链.结论 TPss可与多种肝细胞蛋白相互作用.     

Differential Gene Expression in Apoptosis: Identification of Ribosomal Protein 23K, a Cell Proliferation Inhibitor

Gene expression during the camptothecin-induced apoptotic death of human leukemic U937 cells and mouse T-cell hybridoma QW4.1 cells was studied by the mRNA differential display technique. Ten clones were confirmed to be differentially expressed, nine of which encoded novel sequences. One clone, U3.2, was induced approximately 10-fold in camptothecin-treated cells and was found to be identical to a highly basic 23-kDa human protein which contains basic leucine zipper-like motifs and has recently been identified as the human homologue of the rat ribosomal protein L13a. Northern blot analysis revealed a major mRNA of 0.9 kb and a minor mRNA of 1.3 kb. Overexpression of a full-length 23K cDNA, tagged with a FLAG sequence, in COS-7 cells revealed a predominantly nucleolar localization and the absence of any 23K protein from the cytoplasm. Subsequent transfection studies, using antisense phosphorothioate-modified oligonucleotides, revealed that inhibition of 23K expression results in an increased cell proliferation and greater sensitivity of U937 cells to the effects of camptothecin-induced cell death. Upregulation of 23K expression using a cDNA construct resulted in a decrease in cell proliferation and growth arrest, suggesting a role for 23K protein as a proliferation checkpoint following a cellular insult.     

Critical evaluation of ECV304 as a human endothelial cell model defined by genetic analysis and functional responses: a comparison with the human bladder cancer derived epithelial cell line T24/83

Early reports indicated that ECV304 was a spontaneously-transformed line derived from a Japanese human umbilical vein endothelial cells (HUVEC) culture. Many morphological, immunochemical, and genetic studies provided further evidence that ECV304 was a valuable biomedical research tool and could be used to study processes that include angiogenesis in vitro and signal transduction by a variety of G protein-coupled receptors. However, several distinct differences between ECV304 and HUVEC are now apparent and recent reports have indicated genetic similarity between ECV304 and T24/83, a human bladder cancer cell line. To further assess the utility of ECV304 as a human endothelial cell model, we compared the functional responses of ECV304 and T24/83 to a range of G protein-coupled receptor agonists. We also used DNA fingerprinting to karyotype both ECV304 and T24/83. Both ATP and uridine triphosphate (UTP) stimulated inositol phosphate metabolism in ECV304 without alteration of cAMP levels. Comparative data using selective P2Y receptor agonists indicated that this response, leading to calcium mobilization from intracellular stores, was predominantly mediated by the activation of P2Y2 receptors. Similar responses were recorded from both ECV304 and T24/83 cells. ECV304 expressed a relatively high basal activity of NOS that was reduced by L-NAME and stimulated by P2Y2 receptor agonists. In contrast, P2Y2 receptor activation did not induce prostaglandin synthesis in ECV304. Both ECV304 and T24/83 express receptors for adenosine, adrenaline, and calcitonin, which stimulate adenylate cyclase. Proliferation of ECV304 and T24/83 cells, measured by the incorporation of [3H]thymidine into DNA, was largely serum-independent. This was in contrast to parallel experiments with porcine and bovine aortic endothelial cells that indicated a marked serum-dependent increase in DNA synthesis. Genetic analysis confirmed that ECV304 and T24/83 are identical. ECV304 displays some endothelial characteristics and is useful for the study of receptor pharmacology. However, ECV304 is not of HUVEC origin and is therefore an inappropriate cell line to study endothelial cell biology.